Concepts (266)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 44 | 2022 | 772 | 7.180 |
Why?
|
| Transgender Persons | 17 | 2023 | 95 | 4.970 |
Why?
|
| Homosexuality, Male | 26 | 2022 | 298 | 3.710 |
Why?
|
| Sexual and Gender Minorities | 12 | 2022 | 192 | 3.000 |
Why?
|
| Pre-Exposure Prophylaxis | 9 | 2023 | 137 | 2.330 |
Why?
|
| Sexual Partners | 10 | 2021 | 93 | 2.060 |
Why?
|
| Substance-Related Disorders | 6 | 2021 | 394 | 1.660 |
Why?
|
| Chicago | 24 | 2023 | 1379 | 1.630 |
Why?
|
| Substance Abuse, Intravenous | 3 | 2021 | 54 | 1.510 |
Why?
|
| Sexually Transmitted Diseases | 4 | 2022 | 91 | 1.440 |
Why?
|
| Crime | 2 | 2020 | 36 | 1.400 |
Why?
|
| Residence Characteristics | 3 | 2020 | 197 | 1.380 |
Why?
|
| Social Support | 4 | 2020 | 193 | 1.350 |
Why?
|
| Risk-Taking | 12 | 2021 | 148 | 1.350 |
Why?
|
| Unsafe Sex | 7 | 2020 | 42 | 1.280 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2017 | 64 | 1.260 |
Why?
|
| Sexual Behavior | 14 | 2022 | 302 | 1.190 |
Why?
|
| Gonorrhea | 3 | 2016 | 18 | 1.170 |
Why?
|
| Chlamydia Infections | 3 | 2016 | 25 | 1.170 |
Why?
|
| Anti-HIV Agents | 7 | 2022 | 149 | 1.090 |
Why?
|
| Adolescent | 33 | 2023 | 8979 | 1.070 |
Why?
|
| Young Adult | 30 | 2023 | 5974 | 1.050 |
Why?
|
| Viral Load | 5 | 2021 | 148 | 0.970 |
Why?
|
| Social Stigma | 3 | 2020 | 52 | 0.910 |
Why?
|
| Risk Reduction Behavior | 5 | 2018 | 98 | 0.840 |
Why?
|
| Continuity of Patient Care | 3 | 2020 | 169 | 0.830 |
Why?
|
| Exposure to Violence | 2 | 2018 | 12 | 0.800 |
Why?
|
| Adult | 37 | 2023 | 25640 | 0.800 |
Why?
|
| Anti-Retroviral Agents | 1 | 2020 | 30 | 0.760 |
Why?
|
| Criminals | 1 | 2020 | 33 | 0.740 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 92 | 0.720 |
Why?
|
| Male | 44 | 2023 | 40956 | 0.700 |
Why?
|
| Female | 48 | 2023 | 44507 | 0.690 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2017 | 238 | 0.670 |
Why?
|
| Humans | 64 | 2023 | 86601 | 0.660 |
Why?
|
| Mass Screening | 4 | 2020 | 617 | 0.660 |
Why?
|
| Heterosexuality | 2 | 2015 | 17 | 0.660 |
Why?
|
| Urban Population | 3 | 2018 | 213 | 0.650 |
Why?
|
| Bisexuality | 7 | 2016 | 32 | 0.640 |
Why?
|
| Social Identification | 1 | 2017 | 24 | 0.590 |
Why?
|
| Health Knowledge, Attitudes, Practice | 6 | 2018 | 508 | 0.590 |
Why?
|
| Hepatitis B Antibodies | 1 | 2016 | 15 | 0.580 |
Why?
|
| Stress, Psychological | 5 | 2021 | 313 | 0.570 |
Why?
|
| Ambulatory Care Facilities | 2 | 2015 | 102 | 0.560 |
Why?
|
| Intimate Partner Violence | 1 | 2016 | 20 | 0.560 |
Why?
|
| Hepatitis B | 1 | 2016 | 74 | 0.550 |
Why?
|
| Hospitalization | 2 | 2022 | 848 | 0.550 |
Why?
|
| Condoms | 1 | 2015 | 36 | 0.540 |
Why?
|
| Social Networking | 3 | 2021 | 75 | 0.530 |
Why?
|
| Prisons | 1 | 2014 | 12 | 0.490 |
Why?
|
| Cross-Sectional Studies | 12 | 2023 | 1621 | 0.480 |
Why?
|
| Homosexuality, Female | 5 | 2014 | 15 | 0.480 |
Why?
|
| Health Care Surveys | 2 | 2016 | 278 | 0.470 |
Why?
|
| Hepatitis C | 1 | 2016 | 208 | 0.470 |
Why?
|
| AIDS Serodiagnosis | 1 | 2013 | 25 | 0.470 |
Why?
|
| Prisoners | 1 | 2014 | 40 | 0.470 |
Why?
|
| Sexually Transmitted Diseases, Bacterial | 1 | 2012 | 2 | 0.450 |
Why?
|
| HIV Seronegativity | 1 | 2012 | 12 | 0.450 |
Why?
|
| Disease Progression | 2 | 2016 | 1531 | 0.430 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2017 | 66 | 0.430 |
Why?
|
| Health Personnel | 1 | 2013 | 202 | 0.400 |
Why?
|
| Syphilis, Latent | 1 | 2011 | 1 | 0.400 |
Why?
|
| Socioeconomic Factors | 7 | 2020 | 567 | 0.400 |
Why?
|
| Alcohol Drinking | 2 | 2016 | 266 | 0.390 |
Why?
|
| HIV Seropositivity | 1 | 2011 | 49 | 0.390 |
Why?
|
| Central Nervous System Stimulants | 2 | 2022 | 216 | 0.340 |
Why?
|
| Peer Group | 4 | 2017 | 72 | 0.330 |
Why?
|
| HIV-1 | 2 | 2021 | 163 | 0.320 |
Why?
|
| Longitudinal Studies | 4 | 2020 | 1019 | 0.320 |
Why?
|
| Electronic Health Records | 1 | 2011 | 319 | 0.310 |
Why?
|
| Cohort Studies | 4 | 2021 | 2767 | 0.300 |
Why?
|
| Opioid-Related Disorders | 2 | 2022 | 161 | 0.290 |
Why?
|
| Risk Factors | 6 | 2019 | 5416 | 0.290 |
Why?
|
| Sex Factors | 4 | 2019 | 1054 | 0.290 |
Why?
|
| Middle Aged | 16 | 2022 | 25017 | 0.280 |
Why?
|
| Coinfection | 2 | 2016 | 58 | 0.270 |
Why?
|
| Glycogen | 2 | 2016 | 59 | 0.260 |
Why?
|
| Prevalence | 4 | 2018 | 1239 | 0.250 |
Why?
|
| Medication Adherence | 2 | 2016 | 129 | 0.250 |
Why?
|
| Adolescent Behavior | 2 | 2016 | 106 | 0.240 |
Why?
|
| Vagina | 2 | 2016 | 161 | 0.240 |
Why?
|
| Viremia | 2 | 2021 | 54 | 0.240 |
Why?
|
| Health Promotion | 2 | 2014 | 160 | 0.220 |
Why?
|
| United States | 8 | 2022 | 6665 | 0.220 |
Why?
|
| Syphilis | 2 | 2014 | 27 | 0.210 |
Why?
|
| Aged | 8 | 2021 | 18402 | 0.210 |
Why?
|
| Sexual Health | 1 | 2022 | 14 | 0.210 |
Why?
|
| Hand Disinfection | 1 | 2021 | 17 | 0.210 |
Why?
|
| Vulnerable Populations | 2 | 2020 | 76 | 0.210 |
Why?
|
| Incidence | 5 | 2022 | 1576 | 0.200 |
Why?
|
| Needle Sharing | 1 | 2021 | 14 | 0.200 |
Why?
|
| Sexuality | 1 | 2021 | 40 | 0.200 |
Why?
|
| Masks | 1 | 2021 | 29 | 0.200 |
Why?
|
| Needle-Exchange Programs | 1 | 2021 | 18 | 0.200 |
Why?
|
| Social Environment | 2 | 2020 | 188 | 0.200 |
Why?
|
| Geography | 2 | 2021 | 223 | 0.200 |
Why?
|
| Methamphetamine | 1 | 2022 | 82 | 0.190 |
Why?
|
| Contact Tracing | 1 | 2021 | 29 | 0.190 |
Why?
|
| Psychotherapy, Brief | 1 | 2020 | 10 | 0.180 |
Why?
|
| Women's Health | 3 | 2018 | 100 | 0.180 |
Why?
|
| Attitude of Health Personnel | 2 | 2016 | 636 | 0.180 |
Why?
|
| Vaginosis, Bacterial | 2 | 2016 | 8 | 0.180 |
Why?
|
| Population Surveillance | 2 | 2020 | 219 | 0.180 |
Why?
|
| Internal-External Control | 1 | 2019 | 44 | 0.180 |
Why?
|
| Juvenile Delinquency | 1 | 2019 | 27 | 0.170 |
Why?
|
| Forecasting | 1 | 2020 | 304 | 0.170 |
Why?
|
| Mental Health | 1 | 2020 | 162 | 0.170 |
Why?
|
| Decision Making | 2 | 2015 | 642 | 0.170 |
Why?
|
| Marijuana Smoking | 1 | 2018 | 29 | 0.170 |
Why?
|
| Urban Health | 2 | 2015 | 55 | 0.160 |
Why?
|
| Internet | 2 | 2021 | 312 | 0.160 |
Why?
|
| Logistic Models | 2 | 2020 | 1185 | 0.160 |
Why?
|
| Suburban Population | 1 | 2018 | 6 | 0.160 |
Why?
|
| Focus Groups | 2 | 2015 | 155 | 0.160 |
Why?
|
| Lactobacillus | 2 | 2016 | 21 | 0.160 |
Why?
|
| Alcoholism | 1 | 2020 | 172 | 0.160 |
Why?
|
| Mother-Child Relations | 1 | 2018 | 26 | 0.160 |
Why?
|
| Drug Users | 1 | 2018 | 19 | 0.160 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 857 | 0.160 |
Why?
|
| Racism | 1 | 2019 | 81 | 0.150 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 413 | 0.150 |
Why?
|
| New York City | 1 | 2017 | 59 | 0.150 |
Why?
|
| Population Dynamics | 1 | 2018 | 130 | 0.150 |
Why?
|
| Mothers | 1 | 2018 | 141 | 0.150 |
Why?
|
| Hepatitis B Core Antigens | 1 | 2016 | 9 | 0.140 |
Why?
|
| Marijuana Abuse | 1 | 2016 | 26 | 0.140 |
Why?
|
| Evidence-Based Practice | 1 | 2016 | 45 | 0.140 |
Why?
|
| Reminder Systems | 1 | 2016 | 16 | 0.140 |
Why?
|
| Body Fluids | 1 | 2016 | 36 | 0.140 |
Why?
|
| Cocaine-Related Disorders | 1 | 2016 | 34 | 0.140 |
Why?
|
| Text Messaging | 1 | 2016 | 27 | 0.140 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2015 | 21 | 0.140 |
Why?
|
| Progesterone | 1 | 2016 | 110 | 0.140 |
Why?
|
| Cytomegalovirus | 1 | 2015 | 76 | 0.130 |
Why?
|
| Minority Groups | 2 | 2014 | 137 | 0.130 |
Why?
|
| DNA, Viral | 1 | 2016 | 265 | 0.130 |
Why?
|
| Secondary Prevention | 1 | 2016 | 162 | 0.130 |
Why?
|
| Biomarkers | 3 | 2016 | 1718 | 0.130 |
Why?
|
| Violence | 2 | 2016 | 143 | 0.130 |
Why?
|
| Public Health Surveillance | 1 | 2015 | 21 | 0.130 |
Why?
|
| Estrogens | 1 | 2016 | 200 | 0.130 |
Why?
|
| Trust | 1 | 2015 | 95 | 0.130 |
Why?
|
| Cytomegalovirus Infections | 1 | 2015 | 144 | 0.130 |
Why?
|
| Syphilis Serodiagnosis | 1 | 2014 | 5 | 0.120 |
Why?
|
| Qualitative Research | 1 | 2015 | 256 | 0.120 |
Why?
|
| Social Marketing | 1 | 2014 | 10 | 0.120 |
Why?
|
| Treponema pallidum | 1 | 2014 | 8 | 0.120 |
Why?
|
| Chlamydia trachomatis | 1 | 2014 | 14 | 0.120 |
Why?
|
| Neisseria gonorrhoeae | 1 | 2014 | 16 | 0.120 |
Why?
|
| Smoking Cessation | 2 | 2014 | 230 | 0.120 |
Why?
|
| Smoking Prevention | 1 | 2014 | 43 | 0.120 |
Why?
|
| Mass Media | 1 | 2014 | 26 | 0.120 |
Why?
|
| Glomerular Filtration Rate | 1 | 2015 | 384 | 0.120 |
Why?
|
| Psychology, Adolescent | 1 | 2013 | 29 | 0.120 |
Why?
|
| Antibodies, Bacterial | 1 | 2014 | 95 | 0.120 |
Why?
|
| Patient Compliance | 1 | 2015 | 227 | 0.120 |
Why?
|
| Awareness | 1 | 2014 | 93 | 0.120 |
Why?
|
| Health Services Accessibility | 2 | 2017 | 394 | 0.120 |
Why?
|
| Unemployment | 1 | 2013 | 8 | 0.110 |
Why?
|
| HIV Serosorting | 1 | 2012 | 3 | 0.110 |
Why?
|
| Self Disclosure | 1 | 2012 | 31 | 0.110 |
Why?
|
| Health Education | 1 | 2013 | 100 | 0.110 |
Why?
|
| Attitude to Health | 1 | 2014 | 220 | 0.110 |
Why?
|
| Quality of Life | 1 | 2020 | 1583 | 0.110 |
Why?
|
| Depression | 1 | 2016 | 473 | 0.110 |
Why?
|
| Adaptation, Psychological | 1 | 2013 | 157 | 0.110 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1804 | 0.100 |
Why?
|
| Informed Consent | 1 | 2014 | 266 | 0.100 |
Why?
|
| Aging | 1 | 2015 | 691 | 0.100 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2013 | 487 | 0.100 |
Why?
|
| Urban Health Services | 1 | 2011 | 45 | 0.100 |
Why?
|
| Odds Ratio | 1 | 2013 | 678 | 0.100 |
Why?
|
| Retrospective Studies | 3 | 2014 | 8475 | 0.100 |
Why?
|
| Surveys and Questionnaires | 4 | 2021 | 2501 | 0.100 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 350 | 0.100 |
Why?
|
| Smoking | 2 | 2014 | 609 | 0.100 |
Why?
|
| Pregnancy | 2 | 2016 | 2893 | 0.090 |
Why?
|
| Texas | 2 | 2022 | 101 | 0.090 |
Why?
|
| Illinois | 2 | 2022 | 462 | 0.090 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 6501 | 0.090 |
Why?
|
| Kidney | 1 | 2015 | 1241 | 0.090 |
Why?
|
| Regression Analysis | 1 | 2011 | 596 | 0.090 |
Why?
|
| Microbiota | 1 | 2014 | 381 | 0.080 |
Why?
|
| Health Behavior | 2 | 2021 | 183 | 0.080 |
Why?
|
| Attitude | 2 | 2022 | 127 | 0.080 |
Why?
|
| Cluster Analysis | 2 | 2021 | 369 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 1034 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2021 | 839 | 0.070 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2016 | 493 | 0.060 |
Why?
|
| Program Evaluation | 2 | 2016 | 297 | 0.060 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 3636 | 0.060 |
Why?
|
| HIV | 1 | 2022 | 46 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2014 | 751 | 0.050 |
Why?
|
| Greece | 1 | 2022 | 19 | 0.050 |
Why?
|
| Stakeholder Participation | 1 | 2022 | 19 | 0.050 |
Why?
|
| Infectious Disease Medicine | 1 | 2021 | 7 | 0.050 |
Why?
|
| Naloxone | 1 | 2022 | 59 | 0.050 |
Why?
|
| Policy | 1 | 2022 | 34 | 0.050 |
Why?
|
| Time Factors | 1 | 2011 | 5209 | 0.050 |
Why?
|
| Criminal Law | 1 | 2021 | 11 | 0.050 |
Why?
|
| Communicable Disease Control | 1 | 2021 | 51 | 0.050 |
Why?
|
| Sex Workers | 1 | 2021 | 9 | 0.050 |
Why?
|
| Skin Pigmentation | 1 | 2021 | 40 | 0.050 |
Why?
|
| Louisiana | 1 | 2020 | 17 | 0.050 |
Why?
|
| Probability | 1 | 2021 | 355 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2020 | 2261 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 78 | 0.050 |
Why?
|
| Cities | 1 | 2020 | 40 | 0.050 |
Why?
|
| Poverty | 1 | 2021 | 173 | 0.050 |
Why?
|
| Psychological Theory | 1 | 2020 | 22 | 0.050 |
Why?
|
| Multivariate Analysis | 1 | 2021 | 999 | 0.040 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2019 | 96 | 0.040 |
Why?
|
| Chile | 1 | 2016 | 6 | 0.040 |
Why?
|
| Sex Work | 1 | 2016 | 12 | 0.040 |
Why?
|
| School Teachers | 1 | 2016 | 1 | 0.040 |
Why?
|
| Microbiological Techniques | 1 | 2016 | 24 | 0.040 |
Why?
|
| Baltimore | 1 | 2016 | 36 | 0.040 |
Why?
|
| Florida | 1 | 2016 | 54 | 0.040 |
Why?
|
| Premenopause | 1 | 2016 | 54 | 0.040 |
Why?
|
| Research Design | 1 | 2020 | 594 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2016 | 53 | 0.030 |
Why?
|
| Raltegravir Potassium | 1 | 2015 | 2 | 0.030 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2015 | 23 | 0.030 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2015 | 32 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2020 | 7988 | 0.030 |
Why?
|
| Proteinuria | 1 | 2015 | 107 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2017 | 237 | 0.030 |
Why?
|
| Demography | 1 | 2015 | 177 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2016 | 321 | 0.030 |
Why?
|
| Fluorescent Treponemal Antibody-Absorption Test | 1 | 2014 | 1 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 421 | 0.030 |
Why?
|
| Medical Audit | 1 | 2014 | 41 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2015 | 256 | 0.030 |
Why?
|
| Luminescent Measurements | 1 | 2014 | 57 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 2015 | 286 | 0.030 |
Why?
|
| Social Norms | 1 | 2013 | 9 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2015 | 293 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2014 | 303 | 0.030 |
Why?
|
| Midwestern United States | 1 | 2013 | 76 | 0.030 |
Why?
|
| Transcultural Nursing | 1 | 2013 | 2 | 0.030 |
Why?
|
| Nursing Methodology Research | 1 | 2013 | 11 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2015 | 458 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2015 | 444 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 456 | 0.030 |
Why?
|
| Cultural Competency | 1 | 2013 | 21 | 0.030 |
Why?
|
| Human Rights | 1 | 2013 | 18 | 0.030 |
Why?
|
| Reference Standards | 1 | 2014 | 159 | 0.030 |
Why?
|
| Inservice Training | 1 | 2013 | 38 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2014 | 241 | 0.030 |
Why?
|
| Motivation | 1 | 2016 | 287 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 860 | 0.030 |
Why?
|
| Models, Psychological | 1 | 2013 | 157 | 0.030 |
Why?
|
| ROC Curve | 1 | 2015 | 752 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 1169 | 0.030 |
Why?
|
| Aggression | 1 | 2016 | 320 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2014 | 912 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 351 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 853 | 0.020 |
Why?
|
| Child | 1 | 2022 | 6926 | 0.020 |
Why?
|
| Base Sequence | 1 | 2014 | 2330 | 0.020 |
Why?
|
| Inflammation | 1 | 2015 | 920 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2013 | 574 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 1990 | 0.020 |
Why?
|
| Phylogeny | 1 | 2015 | 1137 | 0.020 |
Why?
|
| Curriculum | 1 | 2013 | 539 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2015 | 4210 | 0.020 |
Why?
|